MIST
Milestone Pharmaceuticals Inc.Company Information
- Company Name
- Milestone Pharmaceuticals Inc.
- CIK
- CIK0001408443
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MIST: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MIST
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-04-16
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 161,938
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 49,483,770
- Shares outstanding
- 124,497,980
- Ownership
- 39.75%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 6.67%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 170 | 71 | 73 | 47 | 42 | 45 | 25 | 13 | 13 | 10 | 14 | 10 | ||||||
| Short Term Investments | 1 | 113 | 33 | 36 | 1 | 11 | 44 | 64 | 70 | 79 | 52 | 66 | ||||||
| Accounts Receivable Net Current | 3 | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 180 | 192 | 112 | 87 | 46 | 60 | 74 | 81 | 87 | 94 | 73 | 85 | ||||||
| Prepaid Expense Current | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 3 | 2 | 2 | 3 | 7 | ||||||
| Inventory Net | 5 | 2 | 1 | - | - | - | - | - | - | - | - | - | ||||||
| Other Receivables Net Current | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 3 | 2 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Property Plant And Equipment Net | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 182 | 194 | 114 | 88 | 47 | 62 | 75 | 83 | 89 | 96 | 75 | 87 | ||||||
Liabilities | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | - | - | 13 | 10 | 9 | 12 | 8 | 5 | 4 | 4 | 7 | 8 | ||||||
| Accounts Payable Current | 8 | 10 | - | - | - | - | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 12 | 10 | - | - | - | - | - | - | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 22 | 21 | 14 | 11 | 9 | 13 | 8 | 5 | 5 | 4 | 7 | 8 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Deferred Revenue Current | 1 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Current | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Long Term Debt | 59 | 58 | 57 | 56 | 55 | 54 | 53 | 52 | 52 | 51 | 50 | 49 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 163 | 158 | 72 | 67 | 65 | 68 | 62 | 59 | 57 | 56 | 58 | 59 | ||||||
| Common Stock Value | 385 | 374 | 353 | 312 | 288 | 288 | 288 | 288 | 288 | 288 | 261 | 261 | ||||||
| Warrants And Rights Outstanding | 56 | 56 | 56 | 56 | 53 | 53 | 53 | 53 | 53 | 53 | 48 | 48 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 63 | 63 | 64 | 66 | 42 | 41 | 40 | 38 | 37 | 35 | 34 | 32 | ||||||
| Stockholders Equity | 18 | 36 | 42 | 21 | -18 | -6 | 13 | 24 | 32 | 40 | 17 | 29 | ||||||
| Retained Earnings Accumulated Deficit | -485 | -457 | -431 | -413 | -401 | -388 | -368 | -355 | -346 | -336 | -326 | -312 | ||||||
| Liabilities And Stockholders Equity | 182 | 194 | 114 | 88 | 47 | 62 | 75 | 83 | 89 | 96 | 75 | 87 | ||||||
| Common Stock No Par Value | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 124 | 118 | 106 | 85 | 53 | 53 | 53 | 53 | 53 | 53 | 33 | 33 | ||||||
| Shares Outstanding | 124 | 118 | 106 | 85 | 53 | 53 | 53 | 53 | 53 | 53 | 33 | 33 | ||||||
| Class Of Warrant Or Right Issued | - | 16 | 16 | - | - | 13 | 13 | - | - | 13 | 10 | - | ||||||
| Class Of Warrant Or Right Outstanding | 16 | 16 | 16 | 16 | 13 | 13 | 13 | 13 | 13 | 13 | 10 | 10 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMilestone Pharmaceuticals Inc. (MIST) — SEC Financial Statements & Analysis
Milestone Pharmaceuticals Inc. (MIST) is a pharmaceutical preparations company, incorporated in A8. Milestone Pharmaceuticals Inc. trades on Nasdaq as: MIST. Milestone Pharmaceuticals Inc. (MIST)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Milestone Pharmaceuticals Inc. carries a market cap of $166.83M, a P/E ratio of -1.99x, a P/B ratio of 9.16x, a P/S ratio of 209.32x, an enterprise value of $56.31M, and an EV/EBITDA multiple of -0.72x. On profitability, it posts an operating margin of -9834.25%, a net margin of -10540.90%, a Return on Equity (ROE) of -35522.62%, a Return on Assets (ROA) of -73.36%, and a Return on Invested Capital (ROIC) of -502.00%. Per share, it reports EPS of $-0.67, free cash flow per share of $-0.50, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 51.29% year-over-year and EPS growth of -34.99% year-over-year. On the balance sheet, it maintains a current ratio of 8.13x, a quick ratio of 7.87x, working capital of $158.14M, a debt-to-equity ratio of 8.97x, a debt ratio of 0.9, an interest coverage ratio of -7.25x, free cash flow of $-61.65M (TTM), and net debt of $-110.52M. Figures sourced from SEC EDGAR.
- Market Cap
- $166.83M
- P/E TTM
- -1.99x
- EPS TTM
- $-0.67
- P/B TTM
- 9.16x
- ROE TTM
- -35522.62%
- ROA TTM
- -73.36%
- Debt To Equity
- 8.97x
- Free Cash Flow TTM
- $-61.65M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Milestone Pharmaceuticals Inc. in?
Milestone Pharmaceuticals Inc. (MIST) operates in the Pharmaceutical Preparations industry.
What exchange does MIST trade on?
Milestone Pharmaceuticals Inc. (MIST) trades on the Nasdaq.
Where is Milestone Pharmaceuticals Inc. incorporated?
Milestone Pharmaceuticals Inc. is incorporated in Quebec, Canada.
When was Milestone Pharmaceuticals Inc. (MIST)'s most recent SEC filing?
Milestone Pharmaceuticals Inc. (MIST)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is MIST's market cap?
Milestone Pharmaceuticals Inc. (MIST) has a market capitalization of $166.83M as of 2026-06-30.
What is MIST's EPS (earnings per share)?
Milestone Pharmaceuticals Inc. (MIST)'s trailing twelve month EPS is $-0.67 as of 2026-06-30.
What is MIST's ROE (return on equity)?
Milestone Pharmaceuticals Inc. (MIST)'s trailing twelve month Return on Equity (ROE) is -35522.62% as of 2026-06-30.
What is MIST's ROA (return on assets)?
Milestone Pharmaceuticals Inc. (MIST)'s trailing twelve month Return on Assets (ROA) is -73.36% as of 2026-06-30.
What is MIST's ROIC (return on invested capital)?
Milestone Pharmaceuticals Inc. (MIST)'s trailing twelve month Return on Invested Capital (ROIC) is -502.00% as of 2026-03-31.
What is MIST's EV/EBITDA?
Milestone Pharmaceuticals Inc. (MIST)'s trailing twelve month EV/EBITDA is -0.72x as of 2026-06-30.